Moderna (MRNA) PT Raised to $38 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $228.44 --0%
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
BofA Securities analyst Alec Stranahan raised the price target on Moderna (NASDAQ: MRNA) to $38.00 (from $34.00) while maintaining a Underperform rating.
You May Also Be Interested In
- Moderna (MRNA) call put ratio 1 call to 1.1 puts into quarter results
- Xometry Inc (XMTR) PT Raised to $117 at RBC Capital
- Fortis Inc. (FTS:CN) (FTS) PT Raised to Cdn$90 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
